Premium
Detection of novel biomarkers of liver cirrhosis by proteomic analysis
Author(s) -
Mölleken Christian,
Sitek Barbara,
Henkel Corinna,
Poschmann Gereon,
Sipos Bence,
Wiese Sebastian,
Warscheid Bettina,
Broelsch Christoph,
Reiser Markus,
Friedman Scott L.,
Tornøe Ida,
Schlosser Anders,
Klöppel Günter,
Schmiegel Wolff,
Meyer Helmut E.,
Holmskov Uffe,
Stühler Kai
Publication year - 2009
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.22764
Subject(s) - cirrhosis , medicine , pathology , fibrosis , hepatic stellate cell , liver biopsy , biomarker , gastroenterology , biopsy , biology , biochemistry
Hepatic cirrhosis is a life‐threatening disease arising from different chronic liver disorders. One major cause for hepatic cirrhosis is chronic hepatitis C. Chronic hepatitis C is characterized by a highly variable clinical course, with at least 20% developing liver cirrhosis within 40 years. Only liver biopsy allows a reliable evaluation of the course of hepatitis C by grading inflammation and staging fibrosis, and thus serum biomarkers for hepatic fibrosis with high sensitivity and specificity are needed. To identify new candidate biomarkers for hepatic fibrosis, we performed a proteomic approach of microdissected cirrhotic septa and liver parenchyma cells. In cirrhotic septa, we detected an increasing expression of cell structure associated proteins, including actin, prolyl 4‐hydroxylase, tropomyosin, calponin, transgelin, and human microfibril–associated protein 4 (MFAP‐4). Tropomyosin, calponin, and transgelin reflect a contribution of activated stellate cells/myofibroblasts to chronic liver injury. The expression of tropomyosin, transgelin, and MFAP‐4, an extracellular matrix associated protein, were further evaluated by immunohistochemistry. Tropomyosin and MFAP‐4 demonstrated high serum levels in patients with hepatic cirrhosis of different causes. Conclusion: A quantitative analysis of MFAP‐4 serum levels in a large number of patients showed MFAP‐4 as novel candidate biomarker with high diagnostic accuracy for prediction of nondiseased liver versus cirrhosis [area under receiver operating characteristic curve (AUC) = 0.97, P < 0.0001] as well as stage 0 versus stage 4 fibrosis (AUC = 0.84, P < 0.0001), and stages 0 to 3 versus stage 4 fibrosis (AUC = 0.76, P < 0.0001). (H EPATOLOGY 2009.)